



News Release

July 11, 2016 – For immediate release

On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season

Holly Springs, NC, July 11, 2016 – Seqirus announced today that it has begun shipment of its portfolio of influenza vaccines to customers in the US market for the 2016-2017 season. The Seqirus portfolio for this season will include Fluvad® (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent® (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine).

About Seqirus

Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG. As the second largest influenza vaccine provider in the world, Seqirus is driven by the promise it shares with parent company, CSL Limited, to provide medicines that help to protect and save lives.

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally, with extensive research and production expertise and manufacturing plants in the US, Europe and Australia and a commercial presence in 20 countries.

Seqirus is part of [CSL Limited](http://www.csl.com) (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employ more than 16,000 people with operations in more than 30 countries.

For more information visit www.seqirus.com and www.csl.com.

#

Media Contact:

Monica Galimberti
Global Communications, Seqirus
monica.galimberti@seqirus.com
seqirus.communications@seqirus.com
Phone: +39 335 7440521 (mobile)